Holen Sie sich die Stockscreener-App
2.63
6.05%
0.15
Handel nachbörslich:
2.62
-0.010
-0.38%
Schlusskurs vom Vortag:
$2.48
Offen:
$2.44
24-Stunden-Volumen:
618.10K
Relative Volume:
0.76
Marktkapitalisierung:
$201.03M
Einnahmen:
$4.72B
Nettoeinkommen (Verlust:
$-123.85M
KGV:
-0.1839
EPS:
-14.2981
Netto-Cashflow:
$-303.12M
1W Leistung:
+25.24%
1M Leistung:
+11.91%
6M Leistung:
-82.02%
1J Leistung:
-82.02%
1-Tages-Spanne:
$2.39
$2.64
1-Wochen-Bereich:
$2.06
$2.64
52-Wochen-Spanne:
$1.885
$2.71
Accendra Health Inc Stock (ACH) Company Profile
Firmenname
Accendra Health Inc
Sektor
Branche
Telefon
(804) 277-4304
Adresse
10900 NUCKOLS ROAD, GLEN ALLEN
Compare ACH vs MCK, COR, CAH, HSIC, AHG
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACH
Accendra Health Inc
|
2.63 | 201.03M | 4.72B | -123.85M | -303.12M | -14.30 |
MCK
Mckesson Corporation
|
884.28 | 108.31B | 397.96B | 4.55B | 9.64B | 34.77 |
COR
Cencora Inc
|
324.80 | 63.18B | 325.78B | 1.64B | 3.61B | 8.3139 |
CAH
Cardinal Health Inc
|
214.05 | 50.37B | 244.67B | 1.68B | 5.51B | 6.9487 |
HSIC
Henry Schein Inc
|
73.94 | 8.48B | 13.18B | 419.00M | 521.00M | 3.2704 |
AHG
Akso Health Group Adr
|
2.22 | 1.90B | 14.85M | -136.07M | 7.23M | -0.4726 |
Accendra Health Inc Stock (ACH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Herabstufung | UBS | Buy → Neutral |
| 2024-07-19 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-13 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-12 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-04-26 | Fortgesetzt | Citigroup | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-03-30 | Fortgesetzt | JP Morgan | Underweight |
| 2022-03-23 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2021-04-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-17 | Hochstufung | UBS | Neutral → Buy |
| 2020-09-25 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-07-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-07-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-07-14 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-05-05 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-04-23 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-01-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-01-07 | Herabstufung | Goldman | Neutral → Sell |
| 2019-11-15 | Hochstufung | CLSA | Underperform → Outperform |
| 2019-09-06 | Bestätigt | BofA/Merrill | Neutral |
| 2019-04-10 | Bestätigt | BofA/Merrill | Neutral |
| 2019-04-03 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-01 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2019-01-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-15 | Hochstufung | CLSA | Underperform → Outperform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2018-12-12 | Herabstufung | Goldman | Buy → Neutral |
| 2018-09-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-11 | Herabstufung | CLSA | Outperform → Sell |
| 2018-04-10 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-26 | Hochstufung | Goldman | Sell → Neutral |
| 2017-11-02 | Herabstufung | HSBC Securities | Buy → Hold |
| 2016-03-24 | Hochstufung | Goldman | Sell → Neutral |
| 2015-12-07 | Herabstufung | Goldman | Neutral → Sell |
| 2015-08-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2012-08-01 | Eingeleitet | HSBC Securities | Underweight |
| 2009-08-05 | Hochstufung | Citigroup | Sell → Buy |
| 2008-12-01 | Herabstufung | HSBC Securities | Neutral → Underweight |
Alle ansehen
Accendra Health Inc Aktie (ACH) Neueste Nachrichten
OMI.N News & Events - Intellectia AI
OMI.N Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
ACH SEC FilingsAccendra Health Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Accendra Health (ACH) details 2025 results, home-care focus and pay votes in 2026 proxy - stocktitan.net
Kevin M. Webb reports 5.61% stake in Accendra Health (NASDAQ: ACH) - Stock Titan
Owens & Minor Appoints Colin Bain as Chief Products Officer, Effective March 30, 2026 - MarketScreener
ACH Stock Price, News & Analysis | Accendra Health - Stock Titan
Vanguard disaggregates holdings; Accendra Health (ACH) listed as 0 shares in amendment - Stock Titan
Accendra Health (ACH) CEO surrenders shares to cover RSU tax obligations - Stock Titan
Accendra Health (ACH) CFO surrenders 11,286 shares for tax withholding - Stock Titan
Accendra Health (ACH) COO surrenders shares for tax withholding, retains stake - stocktitan.net
Accendra Health (ACH) EVP uses 9,347 shares to cover tax withholding - Stock Titan
OMI SEC FilingsOwens & Minor 10-K, 10-Q, 8-K Forms - Stock Titan
Tranche Update on Accendra Health, Inc.'s Equity Buyback Plan announced on February 28, 2025. - marketscreener.com
Fitch Maintains Accendra Health's Rating Watches; Withdraws Ratings - MarketScreener
Is the Options Market Predicting a Spike in Accendra Health Stock? - MSN
Is the Options Market Signaling a Surge in Accendra Health Shares? - Bitget
OMI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Accendra Health CFO granted 85,067 restricted shares | ACH Insider Trading - Stock Titan
ACH Technical Analysis & Stock Price Forecast - Intellectia AI
Owens & Minor, Inc. (OMI) Stock Analysis: Is The 94% Potential Upside Worth The Risk? - directorstalkinterviews.com
Owens & Minor, Inc. (NYSE:OMI) Q4 2025 Earnings Call Transcript - Insider Monkey
Accendra Health, Inc. 2025 Q4ResultsEarnings Call Presentation (NYSE:ACH) 2026-02-25 - Seeking Alpha
Accendra Health (ACH) Price Target Decreased by 12.16% to 3.32 - Nasdaq
Accendra Health (ACH) Reports 2025 Revenue of $2.8B and Shift Toward Core Home-Based Care - Insider Monkey
UBS cuts Accendra Health stock price target on 2026 guidance By Investing.com - Investing.com Canada
UBS cuts Accendra Health stock price target on 2026 guidance - Investing.com South Africa
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bicara Therapeutics Inc. (BCAX), Accendra Health (ACH) and Travere Therapeutics (TVTX) - The Globe and Mail
MSN Money - MSN
Tighter CMS Coverage Rules Put Accendra Health’s Non-Invasive Ventilation Revenue and Liquidity at Risk - TipRanks
Accendra Health: Debt Reduction Creates Long-Term Opportunity (Upgrade) (NYSE:ACH) - Seeking Alpha
Accendra Health (ACH) Faces Lowered Price Target by Leerink Part - GuruFocus
Accendra Health bets on Optum contract, leaner structure - HME News
Accendra Health : Reports Fourth Quarter 2025 Financial Results Prepared Remarks - marketscreener.com
Accendra Health sees 3% YOY growth, embarks on ‘next chapter’ - HME News
Accendra Health earnings missed by $0.01, revenue fell short of estimates - Investing.com Nigeria
Accendra Health Inc (ACH) Q4 2025 Earnings Call Highlights: Navi - GuruFocus
Accendra Health reports Q4 adjusted EPS 21c, consensus 22c - TipRanks
Accendra Health Posts 2025 Results, Guides 2026 Outlook - TipRanks
Accendra Health Reports Fourth Quarter 2025 Financial Results - marketscreener.com
Earnings Scheduled For February 19, 2026 - Benzinga
Q4 2025 Accendra Health Inc Earnings Call Transcript - GuruFocus
Accendra Health Announces Fourth Quarter 2025 Earnings Release Date and Conference Call - Business Wire
ACH Financials: Income Statement, Balance Sheet & Cash Flow | Accendra Health Inc - Stock Titan
Accendra Health Stock Surges on Key Executive Appointment - AD HOC NEWS
Finanzdaten der Accendra Health Inc-Aktie (ACH)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.97%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):